Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.

Profile of Isaac Yi Kim, MD, PhD, MBA

Isaac Yi Kim, MD, PhD, MBAIsaac Yi Kim, MD, PhD, MBA received his PhD and MD from Northwestern University in 1996 and 1997, respectively. During this time, Dr. Kim investigated the role of transforming growth factor-β (TGF-β) in prostate cancer, showing that TGF-β gene expression is frequently downregulated in prostate cancer cells, and identifying a specific genetic alteration in TGF-β receptor type I in prostate cancer. He subsequently completed his urology residency at Baylor College of Medicine, a research fellowship in Urologic Oncology at the National Cancer Institute, and a clinical fellowship in endourology, laparoscopy, and robotics at the University of California, Irvine before joining the faculty at the Rutgers Cancer Institute of New Jersey in 2005. During his postgraduate studies, Dr. Kim extended his laboratory research to bone morphogenetic proteins (BMP-6), the largest family in the TGF-β superfamily. This work lead to a main focus of his more recent work and provided evidence that BMP-6 and cytokine ligand 2 (CCL2) can alter prostate cancer progression and sensitivity to anti-androgen therapy, in part by altering the phenotype of tumor-associated macrophages.